Radium‑223 in patients with metastatic castration‑resistant prostate cancer: Efficacy and safety in clinical practice-Reference-Cited by-同舟云学术

Radium‑223 in patients with metastatic castration‑resistant prostate cancer: Efficacy and safety in clinical practice

Published:2018-11-30 Issue: Volume: Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Prelaj Arsela¹,Rebuzzi Sara²,Buzzacchino Federica¹,Pozzi Chiara¹,Ferrara Carla³,Frantellizzi Viviana¹,Follacchio Giulia¹,Civitelli Liana¹,De Vincentis Giuseppe¹,Tomao Silverio¹,Bianco Vincenzo¹

Affiliation:

1. Department of Radiological, Oncological and Anatomo‑Pathological Sciences, ‘Sapienza’ University of Rome, Policlinico Umberto I, I‑00161 Rome, Italy

2. Department of Medical Oncology, IRCCS San Martino IST, I-16132 Genoa, Italy

3. Department of Public Health and Infectious Diseases, ‘Sapienza’ University of Rome, I‑00185 Rome, Italy

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival outcomes of radium-223 therapy for metastatic castration-resistant prostate cancer following national health insurance reimbursement in Taiwan;Journal of the Chinese Medical Association;2024-05-21

2. Trillin-Mediated Inhibition of NF-κB/COX-2 Signaling Pathways through Upregulation of miR-145-5p Targeting MAP3K11 in Castration-Resistant Prostate Cancer;2024-02-14

3. A Case of Success: Complete Response to Radium-223 in Metastatic Castration-Resistant Prostate Cancer;Cureus;2024-02-05

4. Treatment outcomes of radium-223 in patients with metastatic castration-resistant prostate cancer: An experience before National Health Insurance reimbursement in Taiwan;Journal of the Chinese Medical Association;2023-06-14

5. Assessing Therapeutic Response to Radium-223 with an Automated Bone Scan Index among Metastatic Castration-Resistant Prostate Cancer Patients: Data from Patients in the J-RAP-BSI Trial;Cancers;2023-05-16